CA2614667A1 - 20-ceto-11b-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste - Google Patents
20-ceto-11b-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste Download PDFInfo
- Publication number
- CA2614667A1 CA2614667A1 CA002614667A CA2614667A CA2614667A1 CA 2614667 A1 CA2614667 A1 CA 2614667A1 CA 002614667 A CA002614667 A CA 002614667A CA 2614667 A CA2614667 A CA 2614667A CA 2614667 A1 CA2614667 A1 CA 2614667A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- phenyl
- alkynyl
- alkenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003054 hormonal effect Effects 0.000 title claims 4
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 claims abstract 9
- -1 steroid compound Chemical class 0.000 claims 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 15
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- GHBSPIPJMLAMEP-UHFFFAOYSA-N 6-pentyloxan-2-one Chemical compound CCCCCC1CCCC(=O)O1 GHBSPIPJMLAMEP-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 230000003388 anti-hormonal effect Effects 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 230000035558 fertility Effects 0.000 claims 3
- 238000002657 hormone replacement therapy Methods 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 3
- 230000005070 ripening Effects 0.000 claims 3
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 claims 3
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 230000001911 anti-progestational effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/035,949 | 1998-03-06 | ||
| US09/035,949 US6020328A (en) | 1998-03-06 | 1998-03-06 | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| CA002322862A CA2322862C (fr) | 1998-03-06 | 1999-03-05 | 20-ceto-11.beta.-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002322862A Division CA2322862C (fr) | 1998-03-06 | 1999-03-05 | 20-ceto-11.beta.-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2614667A1 true CA2614667A1 (fr) | 1999-09-10 |
| CA2614667C CA2614667C (fr) | 2012-05-22 |
Family
ID=39133647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2614667A Expired - Lifetime CA2614667C (fr) | 1998-03-06 | 1999-03-05 | 20-ceto-11b-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2614667C (fr) |
-
1999
- 1999-03-05 CA CA2614667A patent/CA2614667C/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2614667C (fr) | 2012-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0256668B1 (fr) | Procédé de traitement du dysfonctionnement sexuel masculin | |
| RU2001111875A (ru) | Омепразол формы А, способ его получения, фармацевтиченский препарат на его основе и способ лечения желудочно-кишечных расстройств | |
| JP2005526741A5 (fr) | ||
| AU5854590A (en) | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | |
| JPH0788303B2 (ja) | ヒスタミン誘導体を含有する医薬組成物 | |
| Michna et al. | The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death | |
| JPS63284195A (ja) | Ｃ１７−２０リアーゼ阻害剤として有用な１７β‐（シクロプロピルアミノ）アンドロスト‐５‐エン‐３β‐オール及び関連化合物 | |
| MXPA05001017A (es) | Composicion conteniendo un 11¦-halogeno esteroide androgenico y un gestageno asi como un anticonceptivo masculino basado en esta composicion. | |
| DK1082338T3 (da) | 17-beta-nitro-11-beta-arylsteroider og derivater heraf med hormonale agonist- eller antagonistegenskaber | |
| JP2008533077A (ja) | 免疫調整剤活性を有する化合物 | |
| Grollman | The comparative activity of desoxycorticosterone and other crystalline derivatives and of purified extracts of the adrenal cortex | |
| Yanai et al. | Inhibition of mammary tumorigenesis by ergot alkaloids and promotion of mammary tumorigenesis by pituitary isografts in adreno-ovariectomized mice | |
| JP2006508951A5 (fr) | ||
| RU2000133319A (ru) | 17βАМИНО И ГИДРОКСИЛАМИНО-11β-АРИЛСТЕРОИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ СВОЙСТВАМИ АГОНИСТОВ ИЛИ АНТАГОНИСТОВ ГОРМОНОВ | |
| EP1922074A1 (fr) | Combinaison de composés pouvant être employée dans le traitement de maladies respiratoires, en particulier de broncho-pneumopathie chronique obstructive (bpco) et d'asthme | |
| CA2614667A1 (fr) | 20-ceto-11b-arylsteroides et leurs derives possedant des proprietes hormonales d'agoniste ou d'antagoniste | |
| RU2001118273A (ru) | 17β-ацил-17α-пропинил-11β-арилстероиды и их производные, обладающие агонистическими или антагонистическими гормональными свойствами | |
| KR20180104180A (ko) | 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들 | |
| JP2003516932A (ja) | モダフィニル及びそのｄ／ｌ鏡像異性体の新規な使用 | |
| KR20090105944A (ko) | 11-(4-아미노페닐)-19-노르프레그나-4,9(10)-디엔-3,20-디온 유도체의 약학적으로 허용가능한 염 | |
| Schlen et al. | The possibility that a component of morphine-induced analgesia is contributed indirectly via the release of endogenous opioids | |
| ES2326787T3 (es) | 17-beta-acil-alfa-propinil-11beta-(amino ciclico)aril-esteroides y sus derivados que tienen propiedades hormonales antagonistas. | |
| CA2622798A1 (fr) | 17.beta.-nitro-11.beta.-arylsteroides et leurs derives presentant des proprietes hormonales agonistes ou antagonistes | |
| TWI672142B (zh) | 黃體激素受體拮抗劑之劑型 | |
| US4060620A (en) | Induction of lactation in nonpregnant dairy animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20190305 |